Author:
Ursul Jean-Paul N’guessan Deto,Coulibaly Songuigama,Eunice Melissa Adouko Apleheni,Ouattara Mahama
Abstract
Quinoline core antimalarials are a major class used for the management of uncomplicated malaria in combination with artemisinin derivatives. Moreover, despite its adverse effects, Quinine remains the reference molecule in the treatment of cerebral malaria due to Plasmodium falciparum. This class also contains molecules such as Mefloquine used in the prevention of malaria. In addition, synthetic derivatives are more manageable with greater therapeutic margins and fewer adverse effects. They have an interest in avoiding the spread of resistance, especially with derivatives possessing gametocytocidal activities. With the presence of a chloroquine-resistant strain of Plasmodium, the use of synthetic derivatives as monotherapy is prohibited to avoid the spread of resistance in this class. In this chapter, we propose to present the class of antimalarials with a quinoline nucleus under its pharmacochemical aspects as well as the prospects for its development to preserve and improve the effectiveness of its representatives in the management of malaria.
Reference21 articles.
1. World Malaria Report 2022. Geneva: World Health Organization; 2022. p. 372. Report No.: Licence: CC BY-NC-SA 3.0 IGO
2. Rosenthal PJ. Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Totowa, NY: Humana Press; 2001. p. 396. (Infectious disease)
3. Hu YQ , Gao C, Zhang S, Xu L, Xu Z, Feng LS, et al. Quinoline hybrids and their antiplasmodial and antimalarial activities. European Journal of Medicinal Chemistry. 2017;139:22-47
4. Vangapandu S, Jain M, Kaur K, Patil P, Patel SR, Jain R. Recent advances in antimalarial drug development. Medicinal Research Reviews. 2007;27(1):65-107
5. Vandekerckhove S, D’hooghe M. Quinoline-based antimalarial hybrid compounds. Bioorganic & Medicinal Chemistry. 2015;23(16):5098-5119